Cargando…
Consequences of Insurance Denials Among U.S. Patients Prescribed Repository Corticotropin Injection for Acute Exacerbations of Multiple Sclerosis
INTRODUCTION: Repository corticotropin injection (RCI; Acthar(®) Gel) is indicated for the treatment of acute exacerbations of multiple sclerosis (MS) in adults. Despite the well-documented clinical and economic benefits of RCI, many patients are denied use of the therapy by third-party payers. This...
Autores principales: | Rice, J. Bradford, Panaccio, Mary P., White, Alan, Simes, Mark, Billmyer, Emma, Downes, Nathaniel, Niewoehner, John, Wan, George J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Healthcare
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8140003/ https://www.ncbi.nlm.nih.gov/pubmed/33170434 http://dx.doi.org/10.1007/s40120-020-00219-y |
Ejemplares similares
-
Cost-Effectiveness of Repository Corticotropin Injection for the Treatment of Acute Exacerbations in Multiple Sclerosis
por: Hunter, Samuel F, et al.
Publicado: (2021) -
Cost-Effectiveness of Repository Corticotropin Injection versus Standard of Care for the Treatment of Active Rheumatoid Arthritis
por: Bindra, Jas, et al.
Publicado: (2021) -
Real-world treatment patterns for repository corticotropin injection in patients with rheumatoid arthritis
por: Busch, Howard, et al.
Publicado: (2022) -
Understanding Predictors of Response to Repository Corticotropin Injection Treatment Among Patients With Advanced Symptomatic Sarcoidosis
por: Bindra, Jas, et al.
Publicado: (2022) -
Pain and Fatigue Improvements in Patients Treated with Repository Corticotropin Injection Across Five Indications: A Narrative Review
por: Girman, Cynthia, et al.
Publicado: (2022)